# Lilly buys a two-year-old biotech for up to $300M. Nobody knows if it works yet. - Date: 2026-04-14 - Category: Biotech & Life Sciences Lilly is paying up to $300M for a two-year-old Houston biotech with zero drugs in human trials. CrossBridge raised $27.6M. That is an 11x premium on a GLP-1 winner converting cash into an oncology bet before anyone knows if it works. ---